Children's Mercy Kansas City

SHARE @ Children's Mercy
Manuscripts, Articles, Book Chapters and Other Papers
2-1-2016

Safety and Immunogenicity of Sequential Rotavirus Vaccine
Schedules.
Romina Libster
Monica McNeal
Emmanuel B. Walter
Andi L. Shane
Patricia Winokur

See next page for additional authors

Follow this and additional works at: https://scholarlyexchange.childrensmercy.org/papers
Part of the Infectious Disease Commons, Medical Immunology Commons, and the Pediatrics
Commons

Recommended Citation
Libster, R., McNeal, M., Walter, E. B., Shane, A. L., Winokur, P., Cress, G., Berry, A. A., Kotloff, K. L., Sarpong,
K., Turley, C. B., Harrison, C. J., Pahud, B. A., Marbin, J., Dunn, J., El-Khorazaty, J., Barrett, J., Edwards, K.
M., . Safety and Immunogenicity of Sequential Rotavirus Vaccine Schedules. Pediatrics 137,
20152603-20152603 (2016).

This Article is brought to you for free and open access by SHARE @ Children's Mercy. It has been accepted for
inclusion in Manuscripts, Articles, Book Chapters and Other Papers by an authorized administrator of SHARE @
Children's Mercy. For more information, please contact library@cmh.edu.

Creator(s)
Romina Libster, Monica McNeal, Emmanuel B. Walter, Andi L. Shane, Patricia Winokur, Gretchen Cress,
Andrea A. Berry, Karen L. Kotloff, Kwabena Sarpong, Christine B. Turley, Christopher J. Harrison, Barbara
A. Pahud, Jyothi Marbin, John Dunn, Jill El-Khorazaty, Jill Barrett, Kathryn M. Edwards, and VTEU Rotavirus
Vaccine Study Work Group

This article is available at SHARE @ Children's Mercy: https://scholarlyexchange.childrensmercy.org/papers/339

Safety and Immunogenicity of
Sequential Rotavirus Vaccine Schedules
Romina Libster, MD, MSc,a,b,c Monica McNeal, MS,d Emmanuel B. Walter, MD, MPH,e Andi L. Shane, MD, MPH, MSc,f Patricia
Winokur, MD,g Gretchen Cress, RN, MPH,g Andrea A. Berry, MD,h Karen L. Kotloff, MD,h Kwabena Sarpong, MD, MPH,i
Christine B. Turley, MD,i Christopher J. Harrison, MD, j Barbara A. Pahud, MD, j Jyothi Marbin, MD,k John Dunn, MD, MPH,l
Jill El-Khorazaty, MS,m Jill Barrett, MPH,m Kathryn M. Edwards, MD,,a for the VTEU Rotavirus Vaccine Study Work Group

BACKGROUND AND OBJECTIVES: Although both licensed rotavirus vaccines are safe and effective,

abstract

it is often not possible to complete the schedule by using the same vaccine formulation.
The goal of this study was to investigate the noninferiority of the immune responses to
the 2 licensed rotavirus vaccines when administered as a mixed schedule compared with
administering a single vaccine formulation alone.
METHODS: Randomized, multicenter, open-label study. Healthy infants (6–14 weeks of age)

were randomized to receive rotavirus vaccines in 1 of 5 different schedules (2 using a
single vaccine for all doses, and 3 using mixed schedules). The group receiving only the
monovalent rotavirus vaccine received 2 doses of vaccine and the other 4 groups received
3 doses of vaccine. Serum for immunogenicity testing was obtained 1 month after the last
vaccine dose and the proportion of seropositive children (rotavirus immunoglobulin A ≥20
U/mL) were compared in all the vaccine groups.
RESULTS: Between March 2011 and September 2013, 1393 children were enrolled and
randomized. Immune responses to all the sequential mixed vaccine schedules were
shown to be noninferior when compared with the 2 single vaccine reference groups.
The proportion of children seropositive to at least 1 vaccine antigen at 1 month after
vaccination ranged from 77% to 96%, and was not significantly different among all the
study groups. All schedules were well tolerated.
CONCLUSIONS: Mixed schedules are safe and induced comparable immune responses when

compared with the licensed rotavirus vaccines given alone.
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WHAT’S KNOWN ON THIS SUBJECT: Rotavirus
vaccines (Rotarix and RotaTeq) are safe and
effective. In clinical practice it is often not possible
for infants to receive the same formulation
for all doses. No studies have addressed the
interchangeability of the 2 different rotavirus
vaccine formulations.
WHAT THIS STUDY ADDS: Mixed rotavirus
vaccine schedules are safe and noninferior in
immunogenicity when compared with each licensed
rotavirus vaccine when administered alone.

To cite: Libster R, McNeal M, Walter EB, et al. Safety
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In the United States, before universal
rotavirus vaccine use in 2006,
rotavirus was the most common
cause of severe gastroenteritis
among children.1,2 It was responsible
for >410 000 doctor visits, 205 000
emergency department visits,
between 55 000 and 70 000
hospitalizations, and 20 to 60
deaths in children younger than 5
years annually.2 Although mortality
attributed to rotavirus is rare in
the United States, in developing
countries, rotavirus is reported to
be associated with >100 000 deaths
each year in children ≤5 years of
age.3
Currently there are 2 rotavirus
vaccines approved by the Food
and Drug Administration that
are licensed for use in the United
States: RotaTeq (RV5) and Rotarix
(RV1). These vaccines use different
principles to achieve broad-range
immunity against diverse strains.4,5
RV5 is a live, oral vaccine that
contains a combination of 5 human/
bovine reassortant rotaviruses.6,7
Three doses of the vaccine are
recommended. RV1 is a liveattenuated human rotavirus vaccine
prepared from a single human
strain (G1P[8]),8,9 and 2 doses are
recommended.
Both vaccines have been shown to
be highly efficacious and safe in large
clinical studies.2,10–12 In contrast to a
previously licensed rotavirus vaccine
(Rotashield),13 only a small increase
in cases of intussusception has been
reported after both RV1 and RV5
vaccinations.14
Although the Advisory Committee
on Immunization Practices (ACIP)
recommended receipt of the same
formulation of rotavirus vaccine
for all doses, in clinical practice
this is often not possible. The aim
of this study was to determine
the noninferiority and safety of 3
different mixed schedules of the 2
licensed rotavirus vaccines compared
with administration of the same
vaccine formulation for each dose.

METHODS
Participants
A randomized, nonblinded (for the
subject and study team), multicenter
study was conducted at 6 primary
Vaccine Testing and Evaluation
Unit (VTEU) sites funded by the
National Institutes of Health and 4
subcontract sites (Children’s Hospital
of Oakland, Oakland, CA; Children's
Mercy Hospital, Kansas City, MO;
Duke University Health System,
Durham, NC; Emory University
School of Medicine, Emory Children's
Center, Atlanta, GA; Group Health
Cooperative, Seattle, WA; St Louis
University, St Louis, MO; University
of Iowa, Iowa City, IA; University of
Maryland, Baltimore, MD; University
of Texas Medical Branch at Galveston,
Galveston, TX; and Vanderbilt
University Medical Center, Nashville,
TN). The Laboratory for Specialized
Clinical Studies, Division of Infectious
Diseases at the Cincinnati Children's
Hospital Medical Center performed
all the immunologic assays.
Eligible subjects were healthy infants
(determined by medical history,
physical examination, and medical
assessment), at least 6 weeks and
≤15 weeks of age at first vaccination.
Parents or legal guardians provided
signed informed consent.
Subjects were excluded from
participation if they had any clinically
significant history of gastrointestinal
disease or other serious medical
conditions, any history of
immunodeficiency, known sensitivity
to any vaccine components, previous
receipt of a rotavirus vaccine, an
acute illness at the time of or in the
previous 48 hours before vaccine
administration (axillary temperature
higher than 100.2°F, >3 looser-thannormal stools, or any episodes of
vomiting), participation in another
study involving an experimental
agent, birth at <37 weeks’ gestation,
receipt of blood and/or blood
products (including immunoglobulin)
within 4 weeks before vaccine

administration, and receipt of any
live vaccine within the past 30 days
or an inactivated vaccine within the
previous 14 days.

Study Objectives
The primary objective of the
study was to determine if the
proportion of seropositive children,
defined as serum anti-rotavirus
immunoglobulin A (IgA) ≥20 U/
mL at 1 month after the last dose
of vaccine,15,16 in each sequential
mixed rotavirus vaccine group, was
noninferior to the proportion of
seropositive infants in the group
receiving a single vaccine formulation
matching the first dose for each
mixed vaccine group. The secondary
objectives were to determine the
neutralizing rotavirus antibody
responses17 to the most common
rotavirus serotypes (G1–G4 and G9)
at 1 month after the last vaccination
and to determine if all the schedules
were safe with no statistically
significant increase in fever, diarrhea,
vomiting, or intussusception
compared with the recommended
schedules of the single vaccine.

Vaccines
RV5 vaccine consists of 5 live
reassortant rotaviruses, containing
G1, G2, G3, G4, and P[8] genes from
human strains on a bovine (WC3
strain) background.7 RV1 vaccine
consists of a live, attenuated human
G1P[8] rotavirus.8

Study Design
After informed consent, infants were
randomized in an unblinded manner
to 1 of 5 different rotavirus vaccine
study groups. The randomization
scheme was prepared by statisticians
at Emmes. Randomization was
stratified by site and used blocks of
either 12 or 13 treatments to balance
treatments across the enrollment
period. The treatment table was
generated using R Foundation for
Statistical Computing (R 2.10.0,
Vienna, Austria).
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All vaccines were administered
according to existing ACIP
guidelines.18 All formulations of
RV5 and RV1 were tracked by lot
numbers and expiration date and
were distributed from a central
monitoring pharmacy. All rotavirus
vaccines were administered
concurrently with the other routinely
administered childhood vaccines
per ACIP guidelines, including
diphtheria and tetanus toxoids
and acellular pertussis, hepatitis
B, Haemophilus influenzae type b
conjugate, pneumococcal conjugate,
and inactivated polio. The concurrent
vaccinations were administered
outside of the study protocol as part
of routine patient care.

Assessment of Immunogenicity
Serum for immunogenicity testing
was obtained 1 month after the last
dose of vaccine. For the study group
1, RV5 only and the mixed rotavirus
vaccine study groups 2, 3, and 5, sera
were obtained at ∼7 months of age.
For the reference RV1 group (group
4), sera were obtained at ∼5 months
of age.

Determination of Antibody
Responses
Enzyme-linked immunoassays
(ELISA) were used to detect and
quantify rotavirus IgA antibody
concentrations.15,19–21 The assay
was validated, shown to be specific
for the detection of serum IgA, and
had acceptable accuracy, precision,
and linearity. Each serum specimen
was individually assayed using viral
lysate of WC3 rotavirus (backbone
for RV5) and 89–12 rotavirus
(precursor to RV1) so that the
ELISA results would not favor either
vaccine. The curve was modeled
by using a 4-parameter logistic fit
regression function. The lower limit
of quantification for the assay was set
at 7.5 U/mL during validation of the
assay. A subject was considered to
have a seropositive result if the IgA
antibody concentration determined
using either virus was ≥20 U/mL.16

Neutralizing antibody was
determined against several
rotavirus strains representing the
common G and P types: Wa(G1P[8]),
DS-1(G2P[4]), P(G3P[8]), ST3(G4P[6
]), VA70(G4P[8]), and CCHMCG9P6(G9P[6]) by using a method
described previously.17 A subject was
considered to have a seropositive
result for neutralizing antibody if the
titer determined against any virus
was ≥10.

Assessment of Safety
Gastrointestinal and systemic
symptoms were recorded for 8 days
after each rotavirus vaccination
by the parents/legal guardians on
a provided memory aid. Diarrhea,
vomiting, fever, intussusception,
hospitalization, and/or any other
event considered severe in the
opinion of the investigator were
recorded. Approximately 1 week
after each vaccination, study staff
telephoned the parents/legal
guardians, reviewed the completed
memory aid, and recorded the
findings on the case report form.
Adverse events were assessed by a
licensed clinician and were graded
for severity and relationship to study
product. Serious adverse events were
reported from enrollment through 1
year of age. A Safety and Monitoring
Committee was established to
monitor the study progress and
address any specific vaccine safety
concerns.

their first dose and the other where
children received RV1 for their first
dose. The primary outcome measure
was to determine noninferiority,
based on a binary outcome of
attainment of serum anti-rotavirus
IgA levels ≥20 U at 1 month after the
last dose of vaccine. Noninferiority
was determined by comparing the
lower bound of the 2-sided 95%
confidence interval for the difference
in a mixed minus the corresponding
single vaccine schedule to the
noninferiority margin of –0.10.
Comparisons were based on a perprotocol analysis.
The sample size for this study was
calculated based on the projected
IgA seropositive response rates
(defined as a titer ≥20) with 80%
power to establish noninferiority for
both substudies: 80% probability
of showing groups 2 (RV5RV1-RV1) and 3 (RV5-RV5-RV1)
were noninferior to Group 1
(RV5-RV5-RV5) and also 80%
probability of showing Group 5 (RV1RV5-RV5) was noninferior to Group
4 (RV1-RV1). Previous estimates
suggested that seroresponse rates
would be at least 90% for RV5
and 80% for RV1, requiring larger
group sizes for the RV1 as first
dose comparison groups.2 The total
sample size was projected to be
1266 subjects, but due to higher than
planned loss to follow-up, the study
population was increased to 1385.

Ethical Considerations

RESULTS

The institutional review boards at
each participating center approved
the protocol and informed consent
documents.

Study Population

Statistical Analysis
The primary analyses focused on
comparisons within the subset of
children receiving the same vaccine
type at the first vaccination. The
trial was considered to contain 2
independent, concurrent trials: one
where children received RV5 for

A total of 1407 infants were screened
for participation and 1393 were
enrolled and randomized to 1 of
the 5 study groups between March
2011 and September 2013. A total
of 1063 children were randomized
to receive 3 doses and 330 were
randomized to receive 2 doses. Of
these, 1384 (99%) received the
first dose, 1309 (94%) received the
second dose, and 958 (90%) of 1063
received the third vaccine dose.

Downloaded from www.aappublications.org/news by guest on September 19, 2018
PEDIATRICS Volume 137, number 2, February 2016

3

Among all randomized children, 1236
(89%) infants completed the study
(Fig 1; Supplemental Table 5). The
characteristics of the subjects are
shown in Table 1 and no differences
were noted among the 5 rotavirus
vaccine dosing groups with respect to
age, gender, and race.

Immunogenicity
The proportion of seropositive
children (IgA ≥20 U/mL) against
at least 1 vaccine antigen (WC3 or
89–12) 1 month after vaccination was
high (77%–96%), and was similar
among all the study groups. All the
sequential mixed vaccine schedules
were shown to be noninferior
when compared with the 2 single
vaccine reference groups (Table 2;
Supplemental Fig 3). Interestingly,
when comparing Groups 4 (RV1 only)
and 5 (RV1-RV5-RV5), the proportion
of infants with rotavirus IgA ≥20 U/
mL against both WC3 and 89–12 was
significantly greater in the sequential
mixed vaccine schedule group than
the 2-dose RV1 schedule (P < .0001).
Geometric Mean Titers (GMTs)
measured by serum anti-rotavirus

FIGURE 1
Flowchart. Enrollment, randomization, and follow-up of the study participants.

IgA levels against WC3 and 89–12
were higher for sequential mixed
vaccine schedule groups 3 and 5
when compared with groups 1 and 4
(Table 2; Fig 2). The Geometric Mean
Ratios comparing GMTs between the
groups are shown in Supplemental
Table 6. The proportion of subjects
who were seropositive for serum
neutralizing rotavirus antibodies

(titer ≥10 post vaccination) against
all the evaluated strains was
comparable between the groups with
sequential mixed schedules shown
to be noninferior when comparing
with reference single vaccine groups
(Table 3). Similar to the IgA results
when comparing groups 4 (RV1-RV1)
and 5 (RV1-RV5- RV5) where RV1
was given first, a higher proportion

TABLE 1 Demographic Characteristics of the Study Population
Study Groups
1a:

Gender, n (%)
Boys
Girls
Ethnicity, n (%)
Non-Hispanic
Hispanic
Race, n (%)
American Indian/
Alaskan
Asian
Black/African
American
Multiracial
Hawaiian/Paciﬁc
Islander
White
Other/Unknown
Age, wk
Mean, STD
a
b

Group RV5-RV5RV5, n = 242

Group 2: RV5RV1-RV1, n = 248

Group 3: RV5RV5-RV1, n = 238

Group 4b: RV1-RV1,
n = 329

Group 5: RV1-RV5-RV5,
n = 327

All Children, n =
1384

118 (48.8)
124 (51.2)

136 (54.8)
112 (45.2)

113 (47.5)
125 (52.5)

153 (46.5)
176 (53.5)

178 (54.4)
149 (45.6)

698 (50.4)
686 (49.6)

201 (83.1)
41 (16.9)

199 (80.2)
49 (19.8)

193 (81.1)
45 (18.9)

277 (84.2)
52 (15.8)

260 (79.5)
67 (20.5)

1130 (81.6)
254 (18.4)

1 (0.4)

0 (0.0)

1 (0.4)

0 (0.0)

1 (0.3)

3 (0.2)

5 (2.1)
60 (24.8)

4 (1.6)
57 (23.0)

4 (1.7)
52 (21.8)

12 (3.6)
80 (24.3)

8 (2.4)
81 (24.8)

33 (2.4)
330 (23.8)

30 (12.4)
0 (0.0)

35 (14.1)
4 (1.6)

37 (15.5)
1 (0.4)

33 (10.0)
1 (0.3)

41 (12.5)
0 (0.0)

176 (12.7)
6 (0.4)

143 (59.1)
3 (1.2)

143 (57.7)
5 (2.0)

139 (58.4)
4 (1.7)

199 (60.5)
4 (1.2)

195 (59.6)
1 (0.3)

819 (59.2)
17 (1.2)

9.2 (1.4)

9.1 (1.2)

9.2 (1.2)

9.1 (1.2)

9.2 (1.4)

9.2 (1.3)

Reference group for Groups 2 and 3.
Reference group for Group 5.
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TABLE 2 Immunogenicity Response (GMTs) Measured by Serum Anti-Rotavirus IgA Levels and Proportion of Seropositive Children at 3 to 6 Weeks After
the Last Dose of Vaccine
ELISA Titers to WC3

ELISA Titers to 89–12

n

GMT (95% CI)

Proportion
of Subjects
Serorespondinga
(95% CI)

n

GMT (95% CI)

Proportion
of Subjects
Serorespondinga
(95% CI)

n

Proportion
Seropositive
to Both WC3
and 89–12b
(95% CI)

n

Proportion
Seropositive to
Either WC3 or
89–12c (95% CI)

Group 1d: RV5RV5-RV5
Group 2: RV5RV1-RV1
Group 3: RV5RV5-RV1

206

294.03 (231.52
to 373.41)
215.81 (168.36
to 276.65)
305.89 (238.61
to 392.13)

0.90 (0.86 to 0.95)

206

0.77 (0.71 to 0.83)

206

0.91 (0.87 to 0.95)

207

0.89 (0.84 to 0.93)

206

207

0.91 (0.87 to 0.95)

0.90 (0.86 to 0.95)

193

0.85 (0.80 to 0.91)

193

0.77 (0.71 to
0.83)
0.86 (0.81 to
0.91)
0.85 (0.80 to
0.90)

206

0.88 (0.84 to 0.93)

60.89 (49.36 to
75.12)
115.72 (94.54
to 141.64)
104.04 (83.03
to 130.38)

194

0.91 (0.86 to 0.95)

Group 4e: RV1RV1
Group 5: RV1RV5-RV5

287

38.06 (31.72 to
45.69)
256.90 (214.44
to 307.77)

0.67 (0.61 to 0.72)

287

0.76 (0.71 to 0.81)

287

0.77 (0.72 to 0.82)

280

0.91 (0.88 to 0.95)

280

0.66 (0.60 to
0.71)
0.89 (0.85 to
0.92)

287

0.93 (0.90 to 0.96)

100.21 (80.58
to 124.63)
212.52 (173.82
to 259.83)

280

0.96 (0.94 to 0.99)

206
194

280

CI, conﬁdence interval; GMT, geometric mean titer.
a Seropositivity is deﬁned as serum anti-rotavirus IgA ≥20 U/mL.
b Post hoc analysis. Subjects with both measurements were included in this endpoint.
c Prespeciﬁed primary endpoint. Subjects with at least 1 measurement were included in this endpoint.
d Reference group for Groups 2 and 3.
e Reference group for Group 5.

FIGURE 2
Geometric mean titers measured by serum anti-rotavirus IgA levels according the vaccine schedule study groups. Immunogenicity response (GMTs)
measured by serum anti-rotavirus IgA levels was comparable for sequential mixed vaccine schedule groups when compared with reference groups
against WC3 and 89–12.

of seropositive neutralizing antibody
titers was found for the sequential
vaccine schedule group, particularly
for neutralizing antibodies to DS-1,
ST3, VA70, and CCHMC-G9P6 viruses
(Table 3)

Safety
Vaccines were well tolerated among
all study groups; the proportion of
subjects with solicited symptoms
is shown in Table 4. No statistically

significant differences were found
when comparing solicited symptoms
(fever, diarrhea, and vomiting)
between sequential schedule
groups 2 (RV5-RV1-RV1) and 3
(RV5-RV5-RV1) versus the single
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0.25 (0.20 to 0.30)
0.55 (0.49 to 0.61)
71/287
154/280
114/287
216/279
68/287
195/280
0.62 (0.57 to 0.68)
0.68 (0.62 to 0.73)

During the study period, 70 infants
were hospitalized, but only 1 of these
hospitalizations was classified to be
associated with the study product.
That subject was a 2-month-old
girl in Group 4 (RV1-RV1) who was
hospitalized for 48 hours at 5 days
after the first vaccine dose with a
diagnosis of gastroenteritis that
resolved without any sequelae. The
infant was also confirmed to have
an Escherichia coli urinary tract
infection.
In addition, hematochezia was
reported in 33 patients and, among
those, 14 were attributed to the
vaccines: 2 in group 1, 1 in group 2,
2 in group 3, 2 in group 4, and 7 in
group 5. All episodes except 1 were
mild and resolved without sequelae.
One episode of intussusception
was reported 91 days after the
last vaccination in an infant who
belonged to group 3, but it was
determined to be unrelated to the
vaccine.

CI, conﬁdence interval.
a Reference group for Groups 2 and 3.
b Reference group for Group 5.

61/287
165/280
260/287
260/280

0.91 (0.87 to 0.94)
0.93 (0.90 to 0.96)

0.21 (0.16 to 0.26)
0.59 (0.53 to 0.65)

179/287
189/280

0.24 (0.19 to 0.29)
0.70 (0.64 to 0.75)

0.40 (0.34 to 0.46)
0.77 (0.72 to 0.83)

0.58 (0.51 to 0.65)
112/194
150/190
145/194
0.57 (0.50 to 0.64)
116/194
176/194

0.91 (0.86 to 0.95)

0.60 (0.53 to 0.67)

111/194

0.75 (0.68 to 0.81)

0.79 (0.73 to 0.85)

0.53 (0.46 to 060)
109/207
152/206
136/207
0.65 (0.58 to 0.71)
112/207
192/207

0.93 (0.89 to 0.97)

0.54 (0.47 to 0.61)

134/207

0.66 (0.59 to 0.72)

0.74 (0.68 to 0.80)

0.53 (0.46 to 0.60)
110/206
161/206
146/206
0.53 (0.46 to 0.60)
127/206

Group 1a: RV5RV5-RV5
Group 2: RV5-RV1RV1
Group 3: RV5-RV5RV1
Group 4b: RV1-RV1
Group 5: RV1-RV5RV5

187/206

0.91 (0.87 to 0.95)

0.62 (0.55 to 0.69)

108/205

0.71 (0.64 to 0.77)

0.78 (0.72 to 0.84)

Proportion of
Seropositive Subjects
(95% CI)
n/N
Proportion of
Seropositive
Subjects (95% CI)
n/N
Proportion of
Seropositive
Subjects (95% CI)
n/N
n/N

Proportion of
Seropositive
Subjects (95% CI)

Proportion of
Seropositive
Subjects (95% CI)

n/N
Proportion of
Seropositive
Subjects (95% CI)
n/N

CCHMC-G9P6 G9P[6]
VA70 G4P[8]
ST3 G4P[6]
P G3P[8]
DS-1 G2P[4]
Wa G1P[8]

Strains of Virus
in Neutralization
Assays

TABLE 3 Proportion of Subjects Who Were Seropositive for Serum Neutralizing Rotavirus Antibodies (Titer ≥10 at 1 Month After Vaccination)

vaccine reference in group 1 (RV5RV5-RV5). Interestingly, the overall
proportion of subjects with fever,
vomiting, and any solicited symptom
was significantly higher in group 5
(RV1-RV5-RV5) when compared with
group 4 (RV1-RV1) reference group.
However, when the associations
between group and presence of
solicited symptoms were stratified
by vaccine dose, there were no
statistically significant differences
between the 2 groups for the first or
second doses of rotavirus vaccine.
Irritability was the most frequently
reported adverse event among all
groups.

DISCUSSION
Since RV5 and RV1 were licensed,
millions of doses have been
delivered worldwide.4,22 During
routine rotavirus immunization
of young children it is likely that
mixed schedules of the 2 vaccines
are administered to infants. In
fact, a recently published study
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0.29 (0.24 to 0.34)
94

−0.09g (−0.16 to
−0.02)

0.20 (0.15 to 0.24)
64

−0.05g (−0.09
to −0.01)

0.24 (0.18 to 0.29)
56

−0.02 (−0.10 to
0.06)
0.03 (−0.05 to
0.11)
—
0.29 (0.23 to 0.34)

0.01 (−0.05 to
0.06)
0.02 (−0.04 to
0.07)
—

70

—
0.27 (0.21 to 0.32)

33
32
−0.06g (−0.11
to −0.01)
49
325

0.09 (0.06 to 0.12)
29
326

0.13 (0.09 to 0.18)
31
236

0.15 (0.11 to 0.19)

28

17

27

0.01 (−0.06 to
0.07)
0.02 (−0.04 to
0.09)
—
0.15 (0.10 to 0.19)
36
245

CI, conﬁdence interval.
a Fever: Axillary temperature ≥100.4°F.
b Diarrhea: ≥3 looser than normal stools a day.
c Vomiting: ≥2 events of vomiting a day.
d Estimates of difference in proportions are not provided for Groups 1 and 4 as they are the reference groups.
e Reference group for Groups 2 and 3.
f Reference group for Group 5.
g Statistically different.

−0.01 (−0.06 to
0.03)

17

22

−0.02 (−0.08 to
0.04)
0.02 (−0.03 to
0.07)
—

18

0.10 (0.06 to
0.13)
0.09 (0.05 to
0.13)
0.08 (0.04 to
0.11)
0.05 (0.03 to
0.08)
0.10 (0.07 to
0.14)
23
—

0.09 (0.05 to
0.13)
0.11 (0.07 to
0.15)
0.07 (0.04 to
0.11)
0.09 (0.05 to
0.12)
0.10 (0.06 to
0.13)
22
—
0.15 (0.11 to 0.20)
37
241

Group 1e: RV5RV5-RV5
Group 2: RV5RV1-RV1
Group 3: RV5RV5-RV1
Group 4f: RV1RV1
Group 5: RV1RV5-RV5

(95% CI)

n
n

Proportion (95% CI)

Differenced

—

64

Differenced (95%
CI)
Proportion (95%
CI)
n
(95% CI)

Proportion
(95% CI)

Differenced

n

Proportion
(95% CI)

(95% CI)

Any Symptom

Differenced
Vomitingc
Diarrheab
Fevera
N

TABLE 4 Proportion of Subjects With Solicited Symptoms

evaluating rotavirus vaccine uptake
in private US practices showed that
3% received a combination of the 2
vaccines.23 However, no data exist,
to our knowledge, on the impact of
sequential schedules on safety or
immunogenicity when compared
with administration of a single
vaccine type in the recommended
schedule.
In this study we showed that mixed
sequential schedules were both
safe and noninferior with respect
to immunogenicity measured
by serum IgA and neutralizing
antibody titers when compared
with their corresponding single
vaccine standard schedules. These
encouraging data are supported by
an earlier study involving precursors
of both vaccines and natural
rotavirus infections. The backbone
of the RV5 vaccine, bovine rotavirus
strain WC3, was administered as a
vaccine to young children during
the 1988–1989 rotavirus season
and 25 (12.1%) of 206 children
had already experienced a natural
rotavirus infection.24 When 8 of these
25 children were administered the
WC3 vaccine, 7 seroconverted to
the G1P[8] Wa strain (a prototype
rotavirus that belongs to the same
G and P types as the circulating
rotaviruses strains found that
season) with 9.7-fold rises in average
G1P[8] neutralizing antibody.25
However, these 7 subjects also
had average rises in neutralizing
antibodies of between 11.5-fold
and 13.7-fold against prototype
rotaviruses of other serotypes,
including the G2P[4] DS-1 strain,
which is completely heterotypic
(not cross reactive) relative to both
the G1P[8] circulating strains and
the G6P[5] WC3 vaccine strain.
These results suggested that if RV1
(based on a human G1P[8] strain and
therefore similar to natural infection
with a G1 rotavirus) and RV5 (a WC3like vaccine) were administered as
RV1 first and RV5 later, the immune
responses could contain high-titer,
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broadly reactive neutralizing
antibodies to both of the common
rotavirus serotypes.
Supporting these previous
observations, we showed that a
higher proportion of seropositive
infants was found for the sequential
vaccine schedule group that
received a first dose of RV1 (group
5), particularly for neutralizing
antibodies to DS-1, ST3, VA70, and
CCHMC-G9P6 viruses.
The proportion of seropositive
children (rotavirus IgA ≥20 U/mL)
against at least 1 homologous vaccine
antigen (WC3 [RV5] or 89–12 [RV1])
at 1 month after vaccination was high
and similar among all study groups.
In addition, mixed vaccine schedules
were shown to be noninferior when
compared with the 2 standard
vaccination schedules with RV5 or
RV1 alone. Moreover, we observed
that the percentage of seropositive
infants was significantly higher for
the sequential rotavirus schedule
(RV1-RV5-RV5) against both WC3
and 89–12 when compared with the
scheme that used RV1 vaccine as a
first dose (RV1-RV1).
As this study was not aimed to
evaluate vaccine efficacy and there
is a gap of knowledge regarding
a precise correlate of protection
for rotavirus vaccine, the clinical
relevance of the differences in
immunogenicity is unclear. However,
our study has clearly shown
that there is not an inhibition in
immunogenicity with the sequential
schedule and supports that vaccines
may be given interchangeably.
Interestingly, the overall proportion
of subjects with fever, vomiting,
and any solicited symptom was
significantly higher in group 5 (RV1RV5-RV5) when compared with the
RV1-RV1 reference group. However,
when the analysis was stratified by
the specific number of doses, there
were no statistical differences for
these solicited symptoms for the first
and second dose, showing that this

pattern could be explained by the
presence of a third vaccine dose in
the group 5 that was absent in the
reference group 4.

formulation represents a safe and an
immunogenic choice.

CONCLUSIONS
Our study has several limitations.
The study was conducted in an
unblinded manner, but it is unlikely
that this influenced reporting
assessments. The study lost 11%
of subjects to follow-up, requiring
a decision to expand enrollment
during study conduct to meet the
projected sample size. Although
this study was not aimed to address
what would be a protective antibody
level and a GMC (Geometric Mean
Concentration) >90 has been
reported previously as a possible
cutoff point for protection,26 we
selected an IgA value of ≥20 U/
mL as a measure of seropositivity
because this was the value used
for earlier RV1 trials.16 Last, this
study was not designed to conduct
surveillance for the occurrence of
rotavirus gastroenteritis during the
study period, and it is possible that
some naturally occurring rotavirus
infections could have influenced
immunogenicity results.
The study also has significant
strengths. State-of-the art
laboratory techniques were used to
evaluate immunogenicity, and the
study followed every participant
until the age of 1 year for safety
outcomes.15,19–21 The sequential
mixed vaccine schedules were shown
to be comparably safe because the
proportion of solicited, unsolicited,
and serious adverse events reported
were similar across all 5 of the
study groups. No increased risk of
intussusception was noted among the
sequential rotavirus vaccine groups,
but the sample size of the study
was inadequate to comprehensively
evaluate this adverse event.
We have shown that, should the
recommended rotavirus vaccine
schedules administration not be
possible, sequential mixed rotavirus

Mixed rotavirus vaccine schedules
are safe and noninferior in immune
responses when compared with
those in which a single formulation
of licensed rotavirus vaccines is
administered alone.
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